key: cord-0895700-7vhjru5e
authors: Marin, E.; Teixido, C.; Arcocha, A.; Castillo, S.; Reyes, R.; Viñolas, N.; Mezquita, L.; Muñoz, S.; Martinez, D.; Jares, P.; Reguart, N.
title: 182P Impact of SARS CoV 2 outbreak in the molecular diagnosis of advanced NSCLC: A retrospective comparative cohort study
date: 2021-04-30
journal: Journal of Thoracic Oncology
DOI: 10.1016/s1556-0864(21)02024-4
sha: 4e1b5470e604e95769b7213cb77a5aa53ad3885f
doc_id: 895700
cord_uid: 7vhjru5e

Background: The SARS CoV 2 coronavirus pandemic has rocked health care systems to the core. Concurrent circulation of COVID 19 has led to service disruptions and delays in the standard procedures related to lung cancer (LC) diagnose and may negatively impact in the management, care and therapeutic patient intervention. We aimed to determine COVID 19 impact in the molecular diagnosis of LC at our institution. Methods: A total of 203 patients (pts) diagnosed with advanced NSCLC with molecular testing requested in the period of 2019–2020 were included. Clinical characteristics and testing patient results evaluated in 2019 and 2020 were compared. The SOC at our institution includes evaluation of DNA and RNA from tissue(t) and/or blood(b) with NGS or nCounter. Single-gene testing by PCR, IHC and/or FISH is used as complementary assays to NGS when tissue is limited or in case of genomic platform service interruptions. Results: A total of 106 and 97 pts were required for molecular testing during 2019 and 2020 respectively. Clinical patient characteristics in both cohorts were very similar and there were no significant differences in the number of DNA-based or RNA-based analyses required between both period times (DNAt p = 0.25;DNAb p = 0.59;RNAt p =.08). The 2019 cohort identified 66 pts (65%) with driver genes: being KRAS the most commonly detected (34%), followed by EGFR 15%, BRAF 4%, ALK 4% and METΔ14 4%. During 2020, driver alterations were found in 56 pts (60%) in a quite similar proportion except for KRAS mutations, 21%. The total number of non evaluable (NE) samples was significantly increased in 2020 compared to 2019 (p =.029). During 2019, 80% of the NE samples could be evaluated by any multiplex technique. On the contrary, during 2020 only 54% of NE were tested by any NGS-based method. Conclusions: Our results show that molecular diagnosis of LC could be preserved during the COVID 19 outbreak. However genomic service disruptions during critical months of the pandemic clearly impacted in the number of pts with a NE result and might explain the differences in the incidence of KRAS mutations observed. While this global crisis rightly demands the world's attention, a continuous and accurate molecular diagnostic testing must be ensured to guarantee quality-care for LC pts. Legal entity responsible for the study: The authors. Funding: Has not received any funding. Disclosure: C. Teixido: Honoraria (self), Personal fees: Pfizer;Honoraria (self), Personal fees: Novartis;Honoraria (self), Personal fees: Takeda;Honoraria (self), Personal fees: MSD;Honoraria (self), Personal fees: Roche;Honoraria (self), Personal fees: Diaceutics;Honoraria (self), Personal fees: AstraZeneca;Research grant/Funding (self), Research funding: Pfizer;Research grant/Funding (self), Research funding: Novartis. R. Reyes: Honoraria (self), Speaker Honoraria: Roche;Honoraria (self), Speaker Honoraria: MSD. L. Mezquita: Honoraria (self), Speaker Honoraria: Bristol-Myers Squibb;Honoraria (self), Speaker Honoraria: Tecnofarma;Honoraria (self), Speaker Honoraria: Roche;Honoraria (self), Speaker Honoraria: Takeda;Advisory/Consultancy: Roche Diagnostics;Advisory/Consultancy: Takeda;Advisory/Consultancy: Roche;Travel/Accommodation/Expenses: Bristol-Myers Squibb;Travel/Accommodation/Expenses: Roche;Research grant/Funding (self): Amgen;Research grant/Funding (self): Bristol-Myers Squibb;Research grant/Funding (self): Boehringer Ingelheim;Speaker Bureau/Expert testimony, Mentorship program with key opinion leaders: AstraZeneca. N. Reguart: Honoraria (self), Speaker Honoraria: MSD;Honoraria (self), Speaker Honoraria: BMS;Honoraria (self), Speaker Honoraria: Roche;Honoraria (self), Speaker Honoraria: Boehringer Ingelheim;Honoraria (self), Speaker Honoraria: Guardant Health;Honoraria (self), Speaker Honoraria: Pfizer;Honoraria (self), Speaker Honoraria: AbbVie;Honoraria (self), Speaker Honoraria: Ipsen;Honoraria (self), Speaker Honoraria: Novartis;Honoraria (self), Speaker Honoraria: AstraZeneca;Honoraria (self), Speaker onoraria: Lilly;Honoraria (self), Speaker Honoraria: Takeda;Honoraria (self), Speaker Honoraria: Amgen;Honoraria (self), Organization of educational events: Amgen;Honoraria (self), Organization of educational events: Roche;Advisory/Consultancy: MSD;Advisory/Consultancy: BMS;Advisory/Consultancy: Roche;Advisory/Consultancy: Boehringer Ingelheim;Advisory/Consultancy: Guardant Health;Advisory/Consultancy: Pfizer;Advisory/Consultancy: AbbVie;Advisory/Consultancy: Ipsen;Advisory/Consultancy: Novartis;Advisory/Consultancy: AstraZeneca;Advisory/Consultancy: Lilly;Advisory/Consultancy: Takeda;Advisory/Consultancy: Amgen;Travel/Accommodation/Expenses: Boehringer Ingelheim;Travel/Accommodation/Expenses: MSD;Travel/Accommodation/Expenses: Roche;Research grant/Funding (self): Novartis;Research grant/Funding (self): Pfizer. All other authors have declared no conflicts of interest.

Background: RWS on immune checkpoint inhibitors treatment (tmnt) outcome by matching data from administrative health flows (AHFs) and clinical records (CRs) may close the gap between randomized clinical trials and real practice. Methods: We primarily investigated median time to tmnt failure (TTF) and overall survival (OS) of NSCLC pts treated with nivolumab (N); mOS in pts with and without early tmnt discontinuation (etd< 6 cycles). Secondarily we investigated: clinical-pathological features predicting etd; mOS and mTTF in patients treated with N vs. docetaxel (D). Pts were anonymously identified from the regional AHFs. Tmnt outcome were confirmed by CRs, as well as predictors of etd. Results: Overall, 237 NSCLC pts treated with N in 21 centres during 2017 were identified from AHF; 141 patients received at least 6 tmnt cycles, 96 received less than 6 cycles. mTTF and mOS in the overall population were 3.8 and 9.8 months, respectively. mOS in patients with and without etd were 3.3 and 18.3 months ( p < 0.0001), respectively. CRs of a subgroup of pts treated with N (n = 52) in 2017 or D (n = 29) in 2014 from a single centre were analyzed for mTTF and mOS. mTTF was 2.3 and 5.6 months respectively in patients treated with D and N (HR 0.33; p < 0.0001); mOS was 6.1 and 12.6 months respectively in patients treated with D and N (HR 0.48; p = 0.0024). These results were confirmed by the multivariate analysis. mOS was 2.9 and 16.5 months in patients with and without etd, respectively (HR 0.23; p < 0.0001). Of note, mOS did not differ between patients treated with D and those treated with N when etd occurred (mOS N: 2.9 vs. D: 6.1 months; HR 0.61; p = 0.15). Main reason for etd was clinical-radiological progression (58%). Through the correlation analysis, etd was significantly associated to the presence of brain metastases, the neutrophil to lymphocyte ratio and the adenocarcinoma histology. Conclusions: Matching data from AHFs and CRs may reliably map tmnt pathway with innovative drugs. Our analysis confirmed a prognostic impact of early N discontinuation and identified brain metastases, high neutrophil to lymphocyte ratio and the adenocarcinoma histology as predictors of early tmnt interruption. Legal entity responsible for the study: Veneto Oncology Network at Istituto Oncologico Veneto IRCCS Padua, Italy. Funding: Regional finalized research funding RSF-2017-00000557. Disclosure: All authors have declared no conflicts of interest.

Impact of SARS CoV 2 outbreak in the molecular diagnosis of advanced NSCLC: A retrospective comparative cohort study Background: The SARS CoV 2 coronavirus pandemic has rocked health care systems to the core. Concurrent circulation of COVID 19 has led to service disruptions and delays in the standard procedures related to lung cancer (LC) diagnose and may negatively impact in the management, care and therapeutic patient intervention. We aimed to determine COVID 19 impact in the molecular diagnosis of LC at our institution. Methods: A total of 203 patients (pts) diagnosed with advanced NSCLC with molecular testing requested in the period of 2019-2020 were included. Clinical characteristics and testing patient results evaluated in 2019 and 2020 were compared. The SOC at our institution includes evaluation of DNA and RNA from tissue(t) and/or blood(b) with NGS or nCounter. Single-gene testing by PCR, IHC and/or FISH is used as complementary assays to NGS when tissue is limited or in case of genomic platform service interruptions. Results: A total of 106 and 97 pts were required for molecular testing during 2019 and 2020 respectively. Clinical patient characteristics in both cohorts were very similar and there were no significant differences in the number of DNA-based or RNA-based analyses required between both period times (DNAt p = 0.25; DNAb p = 0.59; RNAt p = .08). The 2019 cohort identified 66 pts (65%) with driver genes: being KRAS the most commonly detected (34%), followed by EGFR 15%, BRAF 4%, ALK 4% and METΔ14 4%. During 2020, driver alterations were found in 56 pts (60%) in a quite similar proportion except for KRAS mutations, 21%. The total number of non evaluable (NE) samples was significantly increased in 2020 compared to 2019 (p = .029). During 2019, 80% of the NE samples could be evaluated by any multiplex technique. On the contrary, during 2020 only 54% of NE were tested by any NGS-based method. Conclusions: Our results show that molecular diagnosis of LC could be preserved during the COVID 19 outbreak. However genomic service disruptions during critical months of the pandemic clearly impacted in the number of pts with a NE result and might explain the differences in the incidence of KRAS mutations observed. While this global crisis rightly demands the world's attention, a continuous and accurate molecular diagnostic testing must be ensured to guarantee quality-care for LC pts. Legal entity responsible for the study: The authors. Background: Carcinosarcomas (CS) are rare malignant biphasic tumors, that may arise in any organ. In recent years the process of epithelialmesenchymal transition has been implicated in their developmenta notion, that may change treatment options for patients. Here we aimed to analyze some features of lung CS from the country-wide population cancer registry. Methods: A retrospective search in Belarusian cancer registry database was performed using the criteria: "histological diagnosis code: 8980/3" and "location code: C34." All the data found were manually reviewed for the accordance to search criteria. Clinical data, treatment options and outcomes were analyzed for all patients. No formal review of the slides was performed. Results: 45 cases of pulmonary CS were diagnosed in 1995-2016, those being the most frequent non-gynaecological CS. The majority of patients (n = 40, 88.9%) were men. Median age at diagnosis was 67 (47-84) years. Tumor was located in the left lung in 16 (35.6%), right in 29 (64.4%). Major bronchus was affected in 1 (2.2%) case, lobar bronchi in 18 (40.0%), peripheral tumors were seen in 20 (44.4%) patients, in 2 (4.4%) cases tumor location was not clearly stated. Regional lymph node metastases at presentation were seen in 7 (15.6%) patients. The disease was diagnosed in stage I in 14 (31.1%) cases, IIin 8 (17.8%), IIIin 11 (24.4%), IVin 6 (13.3%). Disease progression developed in 17 (37.8%) cases. Median progression free survival was 20 months, not differing for men and women ( p = 0,68). Metastases developed in lungs and bones (n = 7, 15.6%), brain (n = 6, 13.3%), lymph nodes (n = 5, 11.1%), liver (n = 3, 6.7%), pleura, adrenals (n = 2, 4.4%), pericardium, diaphragm, stomach, soft tissues, spine in single patients. Surgical treatment (including palliative) was used in 42 (93.3%) cases, radiotherapy alone in 1 (2.2%), chemotherapy alone in 2 (4.4%). 28 (62.2%) patients died of the disease, 5 (11.1%) more died of other causes, 12 (26.7%) were alive at the time of analysis. Median overall survival was 20 months and didn't differ in men and women (p = 0,71). 1-and 5-year survival were 48.9% and 20%, respectively. Conclusions: Pulmonary CS are rare aggressive tumors, developing predominantly in elderly men. In a small subset of patients long-term survival can be achieved. Legal entity responsible for the study: The authors. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest. Background: BTA prevent skeletal-related events in cancer pts treated with chemotherapy (CT) with no significant impact on overall survival (OS). Among BTA, denosumab (DN) improved OS compared to zoledronic acid (ZA) in a subgroup analysis of aNSCLC pts with bone metastases (BM), while in the SPLENDOUR trial the addition of DN to 1st-line CT in aNSCLC did not improve survival. Currently, the impact of BTA in ICI treated aNSCLC with BM is unclear. Methods: Data from aNSCLC pts with BM treated with ICIs (03/2013-06/2020) in one institution were retrospectively collected. BTA therapy was defined as treatment with DN or ZA administered − 60/+30 days from ICI start and pursued concurrently. HBTB was defined as presence of ≥3 BM. Median OS (mOS) and progression-free survival (mPFS) were estimated with Kaplan-Meier and multivariate analysis was performed by Cox proportional hazards regression model. Results: 161 pts were included, 78 (48%) received BTA. Overall, BTA did not significantly prolong mOS [7.8 months (m) (CI 95% 4.6-10.9) vs 6.8 m (95% CI 3.6-9.9), p = 0.83] or mPFS [2.9 m (95% CI 2.3-3.6) vs 2.1 m (95% CI 1.8-2.3), p = 0.84]. HBTB group included 85 pts: 16 (19%) received DN, 29 (35%) ZA, 40 (46%) did not receive any BTA. In HBTB pts, BTA significantly improve mOS [7.8 m (95% CI 3.5-12) vs 3.5 m (95% CI 2.9-4), p = 0.01] and mPFS [2.6 m (95% CI 1.9-3.3) vs 1.8 m (95% CI 1.5-2.1), p = 0.002). BTA associated benefit in OS [HR 0.59 (95% CI 0.35-0.90), p = 0.02] and PFS [HR: 0.53 (95% CI 0.32-0.83, p = 0.006) was confirmed at multivariate analysis adjusting for PS, number of metastatic sites, therapy line, BM radiotherapy. In HBTB pts, ZA did not prolong mOS [3.8 m (95% CI 0.3-7.3) vs 3.8 m (95% CI 2.6-5.0), p = 0.70], while DN significantly improve both mPFS [2.6 m (95% CI 0.6-4.6) vs 1.8 m (95% CI 1.5-2.1), p = 0.02] and mOS [15.1 m (95% CI 0.1-33.1) vs 3.8 (95% CI 2.6-5.0), p = 0.01] compared to no-BTA. Conclusions: In ICI-treated aNSCLC with BM, BTA did not impact on survival. However, in HBTB subgroup BTA significantly improved PFS and OS, making these pts the best candidates for BTA-ICI concurrent treatment. DN rather than ZA was associated with survival benefit, suggesting a synergy between ICI and RANK ligand inhibition. Legal entity responsible for the study: Fondazione IRCCS Istituto Nazionale dei Tumori. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.

Advisory/Consultancy: Takeda; Advisory/Consultancy: Roche; Travel/ Accommodation/Expenses: Bristol-Myers Squibb; Travel/Accommodation/ Expenses: Roche; Research grant/Funding (self ): Amgen; Research grant/ Funding (self ): Bristol-Myers Squibb; Research grant/Funding (self ): Boehringer Ingelheim

Honoraria (self ), Speaker Honoraria: BMS

Honoraria (self ), Speaker Honoraria: Roche

Speaker Honoraria: Boehringer Ingelheim; Honoraria (self ), Speaker Honoraria: Guardant Health

Honoraria (self ), Speaker Honoraria: Pfizer

Honoraria (self ), Speaker Honoraria: AbbVie

Honoraria (self ), Speaker Honoraria: Ipsen

Honoraria (self ), Speaker Honoraria: Novartis

Honoraria (self ), Speaker Honoraria: AstraZeneca; Honoraria (self ), Speaker Honoraria: Lilly

Honoraria (self ), Speaker Honoraria: Takeda

Honoraria (self ), Speaker Honoraria: Amgen

Honoraria (self ), Organization of educational events: Amgen

Honoraria (self ), Organization of educational events: Roche

Advisory/Consultancy: BMS; Advisory/Consultancy: Roche; Advisory/Consultancy: Boehringer Ingelheim; Advisory/Consultancy: Guardant Health

Advisory/Consultancy: Ipsen; Advisory/Consultancy: Novartis; Advisory/ Consultancy: AstraZeneca

Advisory/Consultancy: Lilly; Advisory/Consultancy: Takeda; Advisory/Consultancy: Amgen

Travel/Accommodation/Expenses: MSD; Travel/ Accommodation/Expenses: Roche; Research grant/Funding (self ): Novartis

Research grant/Funding (self ): Pfizer. All other authors have declared no conflicts of interest